Clinical Trials Logo

Sickle Cell-beta-thalassemia clinical trials

View clinical trials related to Sickle Cell-beta-thalassemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03763656 Completed - Sickle Cell Disease Clinical Trials

Pharmacokinetics of Oral Hydroxyurea Solution

HUPK
Start date: November 20, 2018
Phase: Phase 2
Study type: Interventional

An open label, safety and pharmacokinetic study of oral hydroxyurea solution administered to children from 6 months to 17.99 years (i.e. to the day before 18th birthday), with a 12 to 15 month treatment period for each participant. The study treatment duration will be for 6 months at the maximum tolerated dose [MTD], which is usually reached by 6 months after initiation of treatment. For patients in whom time to MTD is longer than 6 months or not achieved at all, the maximum duration of study treatment will be 15 months.